The recent wave of AI innovation has fallen short of transforming commercial life sciences. In 2025, European biopharmas that ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

In his March 2023 budget, the then UK Chancellor, Jeremy Hunt, accordingly announced that from 2024 the Medicines and ...

"That's a big one," said Trump, as he was handed the WHO order to sign among dozens of others, in a signal of his ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication ...

While AI has revolutionised drug discovery and development in life sciences, its impact in commercialisation has been slower.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

As the race to deliver personalised engagement at scale gains pace, artificial intelligence (AI) has become a critical ...

In Part 4 of our Life Sciences Industry Report, we turn our attention to advanced data analytics, wearable health devices, ...

A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...